$CRVO
CervoMed Inc.

2015 Q2 Form 10-Q Financial Statement

#000143774915015632 Filed on August 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $350.0K $1.210M
YoY Change -71.07% -60.71%
% of Gross Profit
Research & Development $948.8K $266.9K
YoY Change 255.46%
% of Gross Profit
Depreciation & Amortization $6.198K $323.7K
YoY Change -98.09% 4227.51%
% of Gross Profit
Operating Expenses $3.971M $1.801M
YoY Change 120.43% -77.75%
Operating Profit -$1.298M -$1.801M
YoY Change -27.96% -77.75%
Interest Expense $33.34K $136.6K
YoY Change -75.59% 289.31%
% of Operating Profit
Other Income/Expense, Net $1.633K -$2.840M
YoY Change -100.06% -126.86%
Pretax Income -$3.969M -$4.642M
YoY Change -14.49% -287.17%
Income Tax -$186.5K
% Of Pretax Income
Net Earnings -$1.331M -$4.455M
YoY Change -70.12% -289.79%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$8.867M -$49.56M
COMMON SHARES
Basic Shares Outstanding 18.61M 12.87M
Diluted Shares Outstanding 18.61M 12.87M

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.47M $27.14M
YoY Change -39.31% 33825.0%
Cash & Equivalents $2.888M $27.14M
Short-Term Investments
Other Short-Term Assets $1.360M $2.300M
YoY Change -40.87% 7566.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.83M $29.44M
YoY Change -39.43% 17216.6%
LONG-TERM ASSETS
Property, Plant & Equipment $68.78K $56.26K
YoY Change 22.25% 87.54%
Goodwill $12.06M $11.24M
YoY Change 7.24%
Intangibles
YoY Change
Long-Term Investments $250.0K
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $18.82M $25.09M
YoY Change -24.98% 92829.8%
TOTAL ASSETS
Total Short-Term Assets $17.83M $29.44M
Total Long-Term Assets $18.82M $25.09M
Total Assets $36.65M $54.53M
YoY Change -32.78% 27579.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $337.6K $252.1K
YoY Change 33.89% -81.32%
Accrued Expenses $2.230M $1.690M
YoY Change 31.95% -56.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $920.0K
YoY Change -55.77%
Total Short-Term Liabilities $2.568M $4.131M
YoY Change -37.84% -52.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.568M $4.131M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.842M $9.232M
YoY Change -47.55% 5.3%
SHAREHOLDERS EQUITY
Retained Earnings -$82.78M -$66.77M
YoY Change 23.97%
Common Stock $114.6M $112.1M
YoY Change 2.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.81M $45.30M
YoY Change
Total Liabilities & Shareholders Equity $36.65M $54.53M
YoY Change -32.78% 27164.63%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$1.331M -$4.455M
YoY Change -70.12% -289.79%
Depreciation, Depletion And Amortization $6.198K $323.7K
YoY Change -98.09% 4227.51%
Cash From Operating Activities -$1.000M -$4.690M
YoY Change -78.68% 942.22%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$10.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 31.61M
YoY Change 7426.19%
NET CHANGE
Cash From Operating Activities -1.000M -4.690M
Cash From Investing Activities -10.00K 0.000
Cash From Financing Activities 31.61M
Net Change In Cash -1.010M 26.92M
YoY Change -103.75% -89833.33%
FREE CASH FLOW
Cash From Operating Activities -$1.000M -$4.690M
Capital Expenditures -$10.00K $0.00
Free Cash Flow -$990.0K -$4.690M
YoY Change -78.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
RestorGenex Corp
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001053691
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
resx Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
8.32
CY2015Q2 resx Contractual Obligation Due In Next Rolling Twelve Months
ContractualObligationDueInNextRollingTwelveMonths
72203
CY2015Q2 resx Contractual Obligation Due In Next Rolling Year Three
ContractualObligationDueInNextRollingYearThree
49729
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18614968
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015Q2 resx Accrued Board Fees
AccruedBoardFees
55938
CY2014Q4 resx Accrued Board Fees
AccruedBoardFees
55000
CY2015Q2 resx Additional Allocated Sharebased Compensation Expense
AdditionalAllocatedSharebasedCompensationExpense
45953
resx Additional Allocated Sharebased Compensation Expense
AdditionalAllocatedSharebasedCompensationExpense
45953
CY2015Q2 resx Contractual Obligation Due In Next Rolling Year Two
ContractualObligationDueInNextRollingYearTwo
73638
resx Conversion Of Accounts Payable To Notes Payable
ConversionOfAccountsPayableToNotesPayable
resx Conversion Of Accounts Payable To Notes Payable
ConversionOfAccountsPayableToNotesPayable
407998
resx Depreciation Depletion And Amortization Including Discontinued Operations
DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations
12482
resx Depreciation Depletion And Amortization Including Discontinued Operations
DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations
515071
resx Fair Value Of Stock And Stock Warrants Issued As Payment Of Accounts Payable And Accrued Liabilites
FairValueOfStockAndStockWarrantsIssuedAsPaymentOfAccountsPayableAndAccruedLiabilites
resx Fair Value Of Stock And Stock Warrants Issued As Payment Of Accounts Payable And Accrued Liabilites
FairValueOfStockAndStockWarrantsIssuedAsPaymentOfAccountsPayableAndAccruedLiabilites
1361404
resx Fair Value Of Stock And Stock Warrants Issued To Related Party As Payment Of Note Payable
FairValueOfStockAndStockWarrantsIssuedToRelatedPartyAsPaymentOfNotePayable
resx Fair Value Of Stock And Stock Warrants Issued To Related Party As Payment Of Note Payable
FairValueOfStockAndStockWarrantsIssuedToRelatedPartyAsPaymentOfNotePayable
1105475
resx Fair Value Of Stock Issued As Payment Of Note Payable
FairValueOfStockIssuedAsPaymentOfNotePayable
resx Fair Value Of Stock Issued As Payment Of Note Payable
FairValueOfStockIssuedAsPaymentOfNotePayable
517945
resx Gain Loss On Settlement Of Notes Payable
GainLossOnSettlementOfNotesPayable
-876543
CY2014Q2 resx Gain Loss On Settlement Of Notes Payable
GainLossOnSettlementOfNotesPayable
-876543
resx Gain Loss On Settlement Of Notes Payable
GainLossOnSettlementOfNotesPayable
CY2015Q2 resx Gain Loss On Settlement Of Notes Payable
GainLossOnSettlementOfNotesPayable
resx Gains Losses On Extinguishment Of Related Party Debt
GainsLossesOnExtinguishmentOfRelatedPartyDebt
-1829562
CY2014Q2 resx Gains Losses On Extinguishment Of Related Party Debt
GainsLossesOnExtinguishmentOfRelatedPartyDebt
-1829562
resx Gains Losses On Extinguishment Of Related Party Debt
GainsLossesOnExtinguishmentOfRelatedPartyDebt
CY2015Q2 resx Gains Losses On Extinguishment Of Related Party Debt
GainsLossesOnExtinguishmentOfRelatedPartyDebt
CY2014Q4 resx Market Capitalization
MarketCapitalization
66100000
resx Non Cash Stock Warrant Expense
NonCashStockWarrantExpense
261570
resx Non Cash Stock Warrant Expense
NonCashStockWarrantExpense
resx Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsideration
resx Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsideration
6800000
CY2015Q2 resx Number Of Phase I Clinicial Trials Completed
NumberOfPhaseIClinicialTrialsCompleted
2
CY2015Q2 resx Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
1357191
CY2014Q4 resx Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
2286930
CY2014Q2 resx Prior Period Reclassification Adjustment Amortization Of Prepaid Expense Asset
PriorPeriodReclassificationAdjustmentAmortizationOfPrepaidExpenseAsset
286774
resx Prior Period Reclassification Adjustment Amortization Of Prepaid Expense Asset
PriorPeriodReclassificationAdjustmentAmortizationOfPrepaidExpenseAsset
573548
resx Prior Period Reclassification Adjustment Employee And Director Stockbased Compensation Noncash
PriorPeriodReclassificationAdjustmentEmployeeAndDirectorStockbasedCompensationNoncash
291200
CY2014Q2 resx Prior Period Reclassification Adjustment Income Tax Benefit
PriorPeriodReclassificationAdjustmentIncomeTaxBenefit
186470
resx Prior Period Reclassification Adjustment Income Tax Benefit
PriorPeriodReclassificationAdjustmentIncomeTaxBenefit
238129
CY2014Q2 resx Prior Period Reclassification Adjustment Legal And Professional Services
PriorPeriodReclassificationAdjustmentLegalAndProfessionalServices
384604
resx Prior Period Reclassification Adjustment Legal And Professional Services
PriorPeriodReclassificationAdjustmentLegalAndProfessionalServices
516290
resx Prior Period Reclassification Adjustment Loss On Settlement Of Issuing Shares For Liabilities
PriorPeriodReclassificationAdjustmentLossOnSettlementOfIssuingSharesForLiabilities
1285493
CY2014Q2 resx Prior Period Reclassification Adjustment Research And Development Expense
PriorPeriodReclassificationAdjustmentResearchAndDevelopmentExpense
169332
CY2014Q2 resx Prior Period Reclassification Adjustment Stockbased Compensation And Warrant Expense
PriorPeriodReclassificationAdjustmentStockbasedCompensationAndWarrantExpense
141315
resx Prior Period Reclassification Adjustment Stockbased Compensation And Warrant Expense
PriorPeriodReclassificationAdjustmentStockbasedCompensationAndWarrantExpense
291200
CY2015Q2 resx Prior Period Reclassification Adjustment Notes Payable Settlements
PriorPeriodReclassificationAdjustmentNotesPayableSettlements
2706105
CY2014Q2 resx Prior Period Reclassification Adjustment Notes Payable Settlements
PriorPeriodReclassificationAdjustmentNotesPayableSettlements
2706105
CY2015Q2 resx Rent Liability For Facilities No Longer Occupied
RentLiabilityForFacilitiesNoLongerOccupied
808418
CY2014Q4 resx Rent Liability For Facilities No Longer Occupied
RentLiabilityForFacilitiesNoLongerOccupied
808418
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
337589
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
417307
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
98282
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
217663
CY2015Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
414676
CY2014Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
741032
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10356
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6719
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
114569484
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
113437384
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
527189
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
141315
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1132616
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
291200
CY2014Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
321186
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
508005
CY2015Q2 us-gaap Assets
Assets
36654353
CY2014Q4 us-gaap Assets
Assets
42778751
CY2015Q2 us-gaap Assets Current
AssetsCurrent
17829952
CY2014Q4 us-gaap Assets Current
AssetsCurrent
24170817
CY2015Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
2274526
CY2014Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent
2274526
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21883887
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
254964
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16472761
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27139593
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5411126
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26884629
CY2015Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4808766
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18614968
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
18615
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
18615
CY2014Q4 us-gaap Goodwill
Goodwill
12055991
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18614968
CY2015Q2 us-gaap Cost Method Investments
CostMethodInvestments
250000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18614968
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18614968
CY2015Q2 us-gaap Contractual Obligation
ContractualObligation
195570
CY2014Q4 us-gaap Cost Method Investments
CostMethodInvestments
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-238129
CY2015Q2 us-gaap Depreciation
Depreciation
6198
us-gaap Depreciation
Depreciation
12482
CY2014Q2 us-gaap Depreciation
Depreciation
2555
us-gaap Depreciation
Depreciation
7066
CY2015Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6198
CY2014Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
323741
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12482
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
515071
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y332D
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3637492
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6449628
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6449628
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
49278
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
6056
CY2015Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
49278
CY2014Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
6056
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-49278
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6056
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1881278
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1210832
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3842378
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2221690
CY2015Q2 us-gaap Goodwill
Goodwill
12055991
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-238129
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3969322
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4641702
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7485738
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6073536
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-186470
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
229240
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3027926
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-667653
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-461933
CY2015Q2 us-gaap Interest Expense
InterestExpense
CY2014Q2 us-gaap Interest Expense
InterestExpense
136584
us-gaap Interest Expense
InterestExpense
us-gaap Interest Expense
InterestExpense
194878
CY2015Q2 us-gaap Liabilities
Liabilities
4842366
CY2014Q4 us-gaap Liabilities
Liabilities
4613126
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36654353
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42778751
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2567840
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2338600
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
2149002
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32005727
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-278227
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5132899
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5121098
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3969322
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4455232
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7485738
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5835407
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1633
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2840223
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4153
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2900537
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
3970955
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
1801479
us-gaap Operating Expenses
OperatingExpenses
7489891
us-gaap Operating Expenses
OperatingExpenses
3172999
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3970955
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18614968
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1801479
us-gaap Operating Income Loss
OperatingIncomeLoss
-7489891
us-gaap Operating Income Loss
OperatingIncomeLoss
-3172999
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2230251
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1921293
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1633
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2466
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4153
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
446
CY2015Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
167113
CY2014Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
99180
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
250000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28227
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Correction of Prior Period Misstatements</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the fourth quarter of 2014, the Company recorded certain adjustments for misstatements related to prior 2014 interim and prior annual periods that had been deemed immaterial.&nbsp; See Note 2 to the Company&#x2019;s consolidated financial statements for the year ended December 31, 2014, included in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2014, for further information as to the nature of the adjustments recorded in the fourth quarter of 2014.</div></div><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the prior year presentation of research and development expenses for the three months ended June 30, 2014, the Company presented expenses of $403,413. Such amount included $169,332 of general and administrative expenses for the three month period ended June 30, 2014, which was included in research and development expenses in the period as a classification offset to the inclusion of $169,332 of research and development expenses in general and administrative expenses for the three month period ended March 31, 2014. The Company did not separately present research and development expenses in its condensed consolidated statements of operations for the three months ended March 31, 2014 as presented in the prior year. The inclusion of this $169,332 classification offset in the prior period presentation of research and development expenses for the three months ended June 30, 2014 was not appropriate, and represents an immaterial misstatement in the prior year. The prior year presentation of research and development expenses for the six month period ended June 30, 2014 was correct as presented. In the current period presentation of the condensed consolidated statements of operations for the three months ended June 30, 2014, this item has been corrected by decreasing research and development expenses and increasing general and administrative expenses by $169,332.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$2,706,105 of expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations from notes payable settlements was reclassified to &#x201c;loss on settlement of notes payable &#x2013; related parties&#x201d; expenses for $1,829,562 and &#x201c;loss on settlement of notes payable&#x201d; expense for $876,543 in the current period condensed consolidated statements of operations presentation from &#x201c;fair value of common stock exchanged for warrants and notes payable&#x201d; expense in the prior period presentation. Furthermore, the presentation of these amounts in the current period presentation was moved to other expense from operating expenses reflecting the correction of an immaterial prior period misstatement related to the classification of losses on settlement of notes payable.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certain 2014 amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications included:</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$286,774 and $573,548 of amortization expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations from amortizing the prepaid expense asset for general financial advisory and investment banking services described in Note 4 to these condensed consolidated financial statements was reclassified to &#x201c;general and administrative&#x201d; expense in the current period condensed consolidated statements of operations presentation from &#x201c;depreciation and amortization&#x201d; expense where it was presented in the prior year. In the condensed consolidated statements of cash flows, the same amount was reclassified within the &#x201c;cash flows used in operating activities&#x201d; section from &#x201c;depreciation and amortization&#x201d; in the prior period presentation to &#x201c;prepaid expenses, deposits and other assets&#x201d; in the current period presentation.</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$141,315 and $291,200 of expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations presentation from stock-based compensation and warrant expense described in Notes 9 and 10 to these condensed consolidated financial statements was reclassified to &#x201c;general and administrative&#x201d; ($108,490 and $258,375 for the three and six months ended June 30, 2014) and &#x201c;research and development&#x201d; ($32,825 for the three and six months ended June 30, 2014) in the current period condensed consolidated statements of operations presentation from &#x201c;warrants, options and stock compensation&#x201d; expense in the prior period presentation.&nbsp; In the condensed consolidated statements of cash flows, the same amount was reclassified within the &#x201c;cash flows used in operating activities&#x201d; section from &#x201c;warrants, options and stock compensation&#x201d; in the prior period presentation to &#x201c;employee and director stock-based compensation &#x2013; non-cash&#x201d; in the amount of $291,200 in the current period presentation.</div></div><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$384,604 and $516,290 of legal and professional services expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations was reclassified to &#x201c;general and administrative&#x201d; expense in the current period condensed consolidated statements of operations presentation from &#x201c;legal and professional services&#x201d; expense in the prior period presentation. </div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$186,470 and $238,129 of income tax benefit recognized in the three and six months ended June 30, 2014 was reclassified to benefit from income taxes in the current period condensed consolidated statements of operations from other (income) expense in the prior year presentation.</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the condensed consolidated statements of cash flows within net cash (used in) operating activities, $1,285,493 from loss on settlement of issuing shares for liabilities in the prior year presentation was reclassified to loss on settlement of note payable in the amount of $876,543 and accounts payable and accrued liabilities in the amount of $408,950 in the current year presentation.</div></div></div></div></div></div></div></div></div></div></div>
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31605727
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
400000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
79138
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
109034
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68782
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102315
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1115796
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
266906
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2667348
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
436238
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82776112
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75290374
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9483395
CY2015Q2 us-gaap Severance Costs1
SeveranceCosts1
967683
CY2014Q2 us-gaap Severance Costs1
SeveranceCosts1
us-gaap Severance Costs1
SeveranceCosts1
967683
us-gaap Severance Costs1
SeveranceCosts1
us-gaap Share Based Compensation
ShareBasedCompensation
1132616
us-gaap Share Based Compensation
ShareBasedCompensation
291200
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2493350
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P90D
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P1Y
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
0
CY2015Q2 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
0
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38165625
CY2015Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31811987
CY2015Q2 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
685824
CY2014Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of the Company&#x2019;s condensed consolidated financial statements in accordance with U.S.&nbsp;GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s condensed consolidated financial statements and accompanying notes. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions that the Company may undertake in the future, actual results may differ from such estimates and assumptions.</div></div></div></div></div></div></div></div></div></div></div>
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18614968
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12867845
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18614968
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9483395
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18614968
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12867845

Files In Submission

Name View Source Status
0001437749-15-015632-index-headers.html Edgar Link pending
0001437749-15-015632-index.html Edgar Link pending
0001437749-15-015632.txt Edgar Link pending
0001437749-15-015632-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
resx-20150630.xml Edgar Link completed
resx-20150630.xsd Edgar Link pending
resx-20150630_cal.xml Edgar Link unprocessable
resx-20150630_def.xml Edgar Link unprocessable
resx-20150630_lab.xml Edgar Link unprocessable
resx-20150630_pre.xml Edgar Link unprocessable
resx20150630_10q.htm Edgar Link pending
Show.js Edgar Link pending